HSE - PCRS

Application Details

HSE Application ID

HSE100009

HTA Number

25001

HTA Link

https://www.ncpe.ie/maralixibat-livmarli-hta-id-25001/

Drug

Maralixibat

Brand

Livmarli®

Applicant

Mirum Pharmaceuticals International B.V.

Indication Applied For

For the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 2 months of age and older.

Application Date

06/01/2025

Marketing Authorisation Date

09/12/2022

Application Status

NCPE Assessment Completed

30/03/2026

Full Health Technology Assessment Commissioned by HSE

26/02/2025

Rapid Review Completed

04/02/2025

Pricing and Reimbursement Application Complete

06/01/2025